HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PHAT
Phathom Pharmaceuticals, Inc.
PHAT lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PHAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
PHAT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PHAT PE Valuation
PHAT has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 29x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PHAT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
PHAT has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PHAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.22 | — |
| Q3 2026 | -$1.00 | +$2.76 |
| Q2 2026 | -$1.25 | +$3.42 |
| Q1 2026 | -$2.09 | +$3.09 |
| Q4 2025 | -$3.03 | +$2.26 |
| Q3 2025 | -$3.76 | +$1.98 |
| Q2 2025 | -$4.67 | +$0.51 |
| Q1 2025 | -$5.18 | -$0.72 |
| Q4 2024 | -$5.29 | -$1.36 |
PHAT has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PHAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $84.7M | +71% |
| Q2 2026 | $74.3M | +88% |
| Q1 2026 | $58.3M | +104% |
| Q4 2025 | $57.6M | +94% |
| Q3 2025 | $49.5M | +203% |
| Q2 2025 | $39.5M | +439% |
| Q1 2025 | $28.5M | +1392% |
PHAT has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.1% | +31 points |
| Q2 2026 | -5.3% | +146 points |
| Q1 2026 | -27% | +250 points |
| Q4 2025 | -10% | +190 points |
| Q3 2025 | -31% | +402 points |
| Q2 2025 | -152% | +904 points |
| Q1 2025 | -277% | +3382 points |
| Q4 2024 | -200% | N/A |
PHAT has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PHAT on cash generation, producing positive trailing cash flow while its opponent burns cash.
PHAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.7M | +$15.9M |
| Q2 2026 | -$2M | +$60.9M |
| Q1 2026 | -$15.7M | +$69.2M |
| Q4 2025 | -$5.1M | +$58.4M |
| Q3 2025 | -$14.1M | +$49.5M |
| Q2 2025 | -$62.8M | +$7.9M |
| Q1 2025 | -$84.9M | -$15.9M |
| Q4 2024 | -$63.5M | -$19.2M |
PHAT has burned cash in almost every quarter: −$21M over the past year, against −$225M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PHAT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PHAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.4% | +1.1M shares |
| 1 year | +16% | +11.5M shares |
| 3 years | +50% | +28.1M shares |
| 5 years | +128% | +47.6M shares |
| Available history | +244% | +60.2M shares |
PHAT has 85M diluted shares, up 16% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PHAT Net Leverage
PHAT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PHAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.0 | Neutral |
| Stochastic | 13.6 | Oversold |
PHAT's weekly RSI is 37 (neutral) and its Stochastic is 14 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PHAT PE vs Healthcare Sector
PHAT has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PHAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.42 | 3% below |
| 20 week MA | $8.39 | 26% below |
| 50 week MA | $10.9 | 43% below |
| 100 week MA | $9.72 | 36% below |
| 200 week MA | $10.4 | 40% below |
PHAT is in a downtrend: it's below all five of its weekly moving averages, and 40% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over PHAT on returns for 2026, with the stronger performance.
PHAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.0 | $36.3 | +10% |
| 2021 | $36.3 | $19.8 | -46% |
| 2022 | $19.8 | $11.3 | -43% |
| 2023 | $11.3 | $9.13 | -19% |
| 2024 | $9.13 | $8.18 | -10% |
| 2025 | $8.18 | $17.6 | +115% |
| 2026 YTD | $17.6 | $6.23 | -65% |
PHAT's yearly returns have swung widely, from +115% in 2025 to −46% in 2021. It's down 65% so far in 2026.